Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

China Pharma Holdings (CPHI) Preferred Shares Issued (2021)

China Pharma Holdings filings provide 1 years of Preferred Shares Issued readings, the most recent being $7.3 million for Q4 2021.

On a quarterly basis, Preferred Shares Issued changed N/A to $7.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was $5.0 million, a N/A change, with the full-year FY2021 number at $5.0 million, changed N/A from a year prior.
Preferred Shares Issued hit $7.3 million in Q4 2021 for China Pharma Holdings, up from -$2.2 million in the prior quarter.
In the past five years, Preferred Shares Issued ranged from a high of $7.3 million in Q4 2021 to a low of -$2.2 million in Q3 2021.